Natera Inc at JPMorgan Healthcare Conference Transcript
Perfect. Good afternoon, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team here at JPMorgan. Thank you so much for joining us today. I'm joined by the Natera management team. So this is going to be a 40-minute session, roughly 20, 25 minutes of a presentation followed by Q&A. If any of you in the room have a question, feel free to submit it via the portal or you can ping me directly. And with that, I will hand it over to Steve.
Great. Thank you. Thanks for coming. I'm Steve Chapman, I'm the CEO of Natera. We've got Solomon Moshkevich, President of Clinical Diagnostics and Mike Brophy, our Chief Financial Officer. So this is the standard safe harbor statement.
Natera today is the leader in cell-free DNA technology. We're addressing 3 very large underpenetrated markets. We performed more than 10 million tests across 12 different products. We have approximately 175 peer-reviewed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
